The specialist integrated CDMO

Browser not supported

Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:

Search

      
        View Article }}

Article / Jan 05, 2026
An integrated analytical approach to evaluate powder aggregation and predict the aerodynamic performance of homogeneous powdersInternational Journal of Pharmaceutics, 5 January 2026

        View Article }}

Article / Jan 05, 2026
A review of the state-of-the-art: progress in ultrasonic and acoustic techniques for quality assessment in the development and manufacturing of oral solid dosage forms - Part I: theoretical foundations and principles International Journal of Pharmaceutics, 5 January 2026

        View Article }}

Article / Apr 15, 2025
Methodology for rapid development of a continuous loss-in-weight feeding processInternational Journal of Pharmaceutics, 15 April 2025

        View Article }}

Article / Mar 01, 2025
Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLCESI- MS/MSDrug Metabolism and Bioanalysis Letters, March 2025

      View

Press Release / Jan 20, 2026
Hovione’s people-first approach recognized as it achieves Top Employer certification for the fourth consecutive yearHovione has achieved Top Employer certification across all four of its manufacturing sites worldwide for the fourth consecutive year.

      View

Press Clipping / Jan 26, 2026
Hovione, the Portuguese-rooted company that has become indispensable to global pharmaceuticalsL'Express, 26 January 2026

    Drug Substance SustainabilityAt Hovione, sustainability is embedded into every stage. Guided by sustainability-by-design and over 20 years of Green Chemistry expertise, we deliver cleaner, smarter, and more efficient solutions - helping you reduce environmental impact, meet regulatory expectations, and improve process performance.

    Drug Substance Integrated OfferingHovione’s industry-leading particle science and tableting capabilities accelerate your path to commercialization by seamlessly bridging Drug Substance to Drug Product at a single site through a single interface-one project, one team approach.

    Global NetworkOne partner to keep your molecule moving at pace by uniting R&D and Operations to navigate accelerated pathways.

      View

Article / Feb 23, 2026
Hovione’s Diane Villax: “I was not brought up to be a business woman”Executiva, 23 February 2026

Browser not supported

Search

Types

Press Room

Categories

An integrated analytical approach to evaluate powder aggregation and predict the aerodynamic performance of homogeneous powders

A review of the state-of-the-art: progress in ultrasonic and acoustic techniques for quality assessment in the development and manufacturing of oral solid dosage forms - Part I: theoretical foundations and principles

Methodology for rapid development of a continuous loss-in-weight feeding process

Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLCESI- MS/MS

Hovione’s people-first approach recognized as it achieves Top Employer certification for the fourth consecutive year

Hovione, the Portuguese-rooted company that has become indispensable to global pharmaceuticals

Drug Substance Sustainability

Drug Substance Integrated Offering

Global Network

Hovione’s Diane Villax: “I was not brought up to be a business woman”